Mechanismly, upon binding to the surface LUNX, the anti-LUNX antibody reduces LUNX protein levels via antibody-mediated endocytosis and degradation which in turn represses downstream signaling responsible for tumor cell proliferation and survival [42]. The gene discussed is BPIFA1; the disease is neoplasm.